Floatz logo

SOLUBLE FLUORESCEIN

Metastatic Sarcoma

Mayo ClinicSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

109 Active assets in the Metastatic Sarcoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
Inno-206
City of Hope Medical Center
Phase 3BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

SOLUBLE FLUORESCEIN is also rated in:

ovarian cancerDormant
CC
Indicative ·
43 / 100
View asset →
ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →